AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer
AXL expression is associated with reduced immunotherapy efficacy in NSCLC and may serve as a predictive biomarker and therapeutic target.
Authors
- Valérian Dormoy (ORCID: https://orcid.org/0000-0003-1725-371X)
- Myriam Polette (ORCID: https://orcid.org/0000-0001-8173-3246)
- Béatrice Nawrocki‐Raby (ORCID: https://orcid.org/0000-0002-3163-8619)
- A. Durlach (ORCID: https://orcid.org/0000-0002-3330-3505)
- Julien Ancel (ORCID: https://orcid.org/0000-0003-3128-9348)
- Véronique Dalstein (ORCID: https://orcid.org/0000-0003-1311-7147)
- Maxime Dewolf (ORCID: https://orcid.org/0000-0002-7856-8742)
- Nathalie Lalun
- Gaëtan Deslée (ORCID: https://orcid.org/0000-0002-4919-5916)
- Christine Gilles (ORCID: https://orcid.org/0000-0002-6891-4920)
Institutions
- Inserm (FR)
- University of Liège (BE)
- Centre Hospitalier Universitaire de Reims (FR)
- Hôpital Maison Blanche (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108853
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Institut National de la Santé et de la Recherche Médicale
- Université de Reims Champagne-Ardenne